Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent
Treatment with a proprietary antisense agent was associated with significant reductions in levels of lipoprotein(a) in a phase 2 study of patients with established coronary or peripheral vascular disease and elevated Lp(a).
Related stories
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023
- New SNOMED Codes for FH DNA test results!
- Healthcare Professional Dietary Survey Prize Draw 2022
- Opportunity to join the NICE CG181 guideline committee
- NICE launches review of methods and processes for health technology evaluation
- The Essential Cholesterol Programme for Primary Care
- Add on to take back control. Do we have the solutions to the gaps in our lipid treatment pathway?
- Familial Hypercholesterolaemia: from Epidemiology to Genetics – a paradigm shift?